[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastrointestinal-function\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastrointestinal-function":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,67,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100639650","oral-lactulose-for-gastrointestinal-recovery-after-complex-appendectomy-100639650",false,"NCT07589465","Oral Lactulose for Gastrointestinal Recovery After Complex Appendectomy","Oral Lactulose for Postoperative Gastrointestinal Recovery After Complex Appendectomy: A Prospective Triple-Blind Placebo-Controlled Single-Center Randomized Trial","Inclusion Criteria:\n\n* 1.Age ≥18 years.2.Complicated appendicitis confirmed by SAS2.0 score, intraoperative findings, or pathology.3.Undergoing appendectomy (open or laparoscopic).4.Able to provide informed consent and comply with follow-up.\n\nExclusion Criteria:\n\n* 1.Preoperative intestinal obstruction, IBD, or intestinal tumor.2.Planned postoperative fasting \\>48 hours.3.Hypersensitivity to lactulose or placebo.4.Severe organ dysfunction (ASA ≥IV).5.Pregnancy or lactation.6.Cognitive or psychiatric disorder impairing follow-up.","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a prospective, triple-blind, placebo-controlled, single-center randomized clinical trial to evaluate the efficacy and safety of early oral lactulose for promoting postoperative gastrointestinal functional recovery in patients undergoing appendectomy for complicated appendicitis. Eligible patients aged ≥18 years with complicated appendicitis confirmed by preoperative SAS 2.0 score, intraoperative findings, or postoperative pathology will be randomly assigned 1:1 to receive oral lactulose or placebo on postoperative day 1 and day 2. The primary outcome is time to GI-2 (time from surgery to the later of first defecation or first tolerance of solid food). Secondary outcomes include time to first flatus, defecation rate within 72 hours, postoperative nausea and vomiting, length of hospital stay, medical costs, postoperative complications, and lactulose-related adverse events. A total of 150 patients will be enrolled. This study aims to provide high-level evidence for optimizing postoperative management in patients with complicated appendicitis.",[26,27,28],"Ileus Postoperative","Gastrointestinal Function","Complicated Appendicitis","RECRUITING","2026-06-20",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":35,"type":20},"2026-06-21",{"date":37,"type":20},"2029-06-30",{"name":39,"class":40},"Nanchong Central Hospital","OTHER_GOV",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100628504","probiotic-intervention-in-constipation-100628504","NCT07462494","Probiotic Intervention in Constipation","To Evaluate the Efficacy and Safety of Probiotics in Alleviating Constipation in Adults Through a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Aged 18-65 years.\n2. Patients with constipation, defined as fewer than three bowel movements per week and\u002For Bristol Stool Form Scale (BSFS) types 1-2.\n3. Able to comply with the study protocol and complete the study procedures.\n4. Participants who have voluntarily signed the informed consent form.\n5. Participants (including male participants) must have no plans for pregnancy from 14 days before screening until 6 months after the end of the study and must agree to use effective contraception during this period.\n\n   \\-\n\nExclusion Criteria:\n\n1. Individuals who have recently taken products with similar functions to the investigational product that may affect the evaluation of study outcomes.\n2. Participants who plan to change their dietary habits during the study period.\n3. Patients with severe allergies or immunodeficiency.\n4. Women who are pregnant, breastfeeding, or planning to become pregnant.\n5. Patients with severe diseases of major organs such as the cardiovascular system, lungs, liver, or kidneys, or those with severe metabolic diseases (e.g., diabetes or thyroid disorders), malignant tumors, or severe immune system diseases.\n6. Individuals who have used antibiotics within the past two weeks.\n7. Individuals with severe psychological or psychiatric disorders.\n8. Participants who fail to take the investigational product as required or fail to attend scheduled follow-up visits, resulting in an inability to determine treatment efficacy.\n9. Any other participants considered unsuitable for participation in the study by the investigator.\n\n   \\-",true,"65 Years",{"count":52,"type":20},30,[23],"To evaluate the effects of probiotic intervention on gastrointestinal function in patients with constipation after 4 weeks of treatment, and to explore its potential effects on immune status and bone metabolism.",[27],"NOT_YET_RECRUITING","2026-06-05",{"date":59,"type":33},"2026-06-09",{"date":61,"type":20},"2026-06-10",{"date":63,"type":20},"2026-12-30",{"name":65,"class":66},"Wecare Probiotics Co., Ltd.","INDUSTRY",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":41},"100622795","impact-of-weizmannia-bacillus-coagulans-jbi-yz63-on-gut-health-and-fecal-microbiome-changes-100622795","NCT07388264","Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes","Examining the Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes","WIZ","Inclusion Criteria Ages of 18 - 50 years Average daily bloating score \\>5 on question 3 of the Modified daily Abdominal, Gas, and Bloating Questionnaire and\u002For bloating for \\>5 days during the past 14 days Body mass index (BMI) 18.5 - 29.9 kg\u002Fm2 (Inclusive) (Individuals \\>29.9 kg\u002Fm2, but \\\u003C25% fat for men and \\\u003C30% fat for women will be accepted into the study. The cohort average of body mass index will not exceed 29.9 kg\u002Fm2) Weight stable for the past three months (defined as less than a 5% variation in body mass over this time) Determined to be healthy through completion of a health history questionnaire Subject agrees to maintain their existing dietary patterns throughout the study period and to report to study investigators any changes particularly as they relate to probiotic-containing or fermented foods Subject agrees to refrain from alcohol, caffeine, and strenuous exercise for 24 hours prior to each test day.\n\nMinimum baseline physical activity level (defined as at least 30 minutes of moderate intensity exercise at least 4 days per week for the past 3 months) Subject is willing and able to comply with the study protocol. Study participant is not currently enrolled in another clinical trial that involves the administration of some investigative agent Subject has given voluntary, written, informed consent to participate in the study.\n\nExclusion Criteria Positive medical history and\u002For is currently being treated for some form of heart disease, cardiovascular disease Currently being treated for kidney disease, renal failure, or has dialysis performed on regular intervals Has liver disease or some form of clinically diagnosed hepatic impairment Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose \\> 126 mg\u002FdL) Diagnosed with or is being treated for some form of thyroid disease Diagnosed with major affective disorder or other psychiatric disorder that required hospitalization in the prior year Diagnosed with some form of immune disorder (i.e., HIV\u002FAIDS) History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).\n\nParticipant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea) Participant has been treated for a gastrointestinal related disorder, complication, or disorder within the past 30 days Positive medical history for any neurological condition or neurological disease Diagnosed with or being treated for any endocrinological disorder or currently used any form of hormone replacement (prescribed\u002Fdoctor ordered or not) Women with a history of hormone-related conditions such as endometriosis, fibroids, polycystic ovary syndrome Currently prescribed for the first time statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) within the past 6 months or has had their dosage or medication changed within the past 6 months Currently prescribed for the first time hypertension medication (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, Vasodilators, etc.) within the past 6 months or has had their dosage or medication changed within the past 6 months Current antibiotic use or other prescription or over-the-counter medications that may impact study outcomes Have a known sensitivity or allergy to any of the study products Blood donation in past 60 days Current smoker (average of \\> 1 pack per week within the past 3 months) or has quit within the past six months. This includes all forms of nicotine They plan major changes in lifestyle (i.e., diet, dieting, exercise level, travel, etc.) during the study Competitive athletes will be excluded History of alcohol or substance abuse in the 12 months prior to screening Current use of anabolic steroids (medically prescribed or otherwise) Receipt or use of an investigational product in another research study within 30 days of beginning the study protocol Report taking a probiotic or other dietary supplement know to impact digestion or gut function in the past 30 days Recent history (\\\u003C3 months) of exercise training or weight loss (\\> 5%) Currently following a ketogenic or low carbohydrate diet within the past 30 days.\n\nWomen who are pregnant, planning to become pregnant, or lactating currently or within the past six months Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data","50 Years",{"count":52,"type":20},[23],"This study will evaluate the effects of supplementation with Weizmannia (Bacillus) coagulans JBI-YZ6.3 on gastrointestinal health in healthy, physically active adults. The primary objective is to determine whether daily intake of this probiotic strain improves symptoms of constipation and related gastrointestinal function compared with placebo.\n\nApproximately 30 healthy men and women aged 18 to 50 years will be enrolled in a randomized, double-blind, placebo-controlled, crossover trial. Participants will complete two 4-week supplementation periods, one with Weizmannia (Bacillus) coagulans JBI-YZ6.3 and one with placebo, separated by a 4-week washout period. The total duration of participation will be approximately 13 to 14 weeks, including screening and testing visits.\n\nGastrointestinal symptoms will be assessed at baseline and after each supplementation period using validated questionnaires, with particular focus on the constipation domain of the Gastrointestinal Symptom Rating Scale (GSRS). Secondary outcomes will include additional gastrointestinal symptom domains and markers of perceived gut comfort and function.\n\nThis study is designed to determine whether supplementation with Weizmannia (Bacillus) coagulans JBI-YZ6.3 produces clinically meaningful improvements in gastrointestinal symptoms in physically active adults compared with placebo.",[80,81,82,27],"Gastrointestinal Symptoms","Constipation","Gut Health","2026-01-28",{"date":85,"type":33},"2026-02-05",{"date":87,"type":33},"2025-06-15",{"date":89,"type":20},"2026-06-15",{"name":91,"class":92},"Lindenwood University","OTHER",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":41},"100599177","probiotics-and-non-organic-gastrointestinal-improvement-100599177","NCT07081100","Probiotics and Non-Organic Gastrointestinal Improvement","Study on the Effect of Probiotics on Improving Gastrointestinal Function in Patients With Non-organic Gastrointestinal Dysfunction","Inclusion Criteria:\n\n* Voluntarily sign the informed consent form and agree to participate in the study.\n* Ability to complete the study according to the trial protocol requirements.\n* Aged 18-65 years.\n* Clinical diagnosis of non-organic gastrointestinal dysfunction (e.g., functional dyspepsia, functional constipation) without other serious organic diseases.\n\nExclusion Criteria:\n\n* Use of drugs affecting intestinal flora (antibiotics, probiotics, intestinal mucosal protectants, herbal medicines, etc.) for \\>1 week within 1 month prior to screening.\n* Short-term use of products with functions similar to the investigational product, which may interfere with result interpretation.\n* Antibiotic use during the study period.\n* History of severe systemic diseases or malignancies.\n* Allergy to any ingredient in the compound probiotic freeze-dried powder used in the trial.\n* Pregnancy, lactation, or plans for pregnancy in the near future.\n* Inability to participate due to personal reasons.\n* Other conditions deemed unsuitable by the investigators.",{"count":101,"type":20},50,[23],"To verify the improvement of gastrointestinal function in patients with non-organic gastrointestinal dysfunction after 4 weeks of intervention with compound probiotics.",[27],"2025-07-28",{"date":107,"type":33},"2025-07-31",{"date":109,"type":20},"2025-08-05",{"date":111,"type":20},"2026-03-01",{"name":65,"class":66}]